• Login
    • Join
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Manufacturing
    • Markets
    • Top 10 Orthopedic Device Firms
    • Buyers' Guide
    • Events
    • More
  • Magazine
  • News
  • Exclusives
  • Manufacturing
  • Markets
  • Top 10 Orthopedic Device Firms
  • Buyers' Guide
  • Events
  • Current & Past Issues
    Features
    Departments
    Columns
    Editorial
    Digital Edition
    Subscribe Now
    Advertise Now
    Editorial Guidelines
    eNewsletter Archive
    Top Features
    From Nitinol to Nanotubes: A Materials Science Roundtable

    In Good Repair: Trauma Technologies Under Review

    Anxious Undertones: A Review of 2019

    Automated Analysis Advantages for Part Validation

    Tried and True Metalworking
    Breaking News
    Certifications
    Clinical Trials
    Device Approvals & Patents
    Financial & Deals
    International
    Market Data & Trends
    OEM News
    People
    Product & Service Releases
    Products
    Quality, Recalls & Risk
    Regulatory & Legal
    Supplier & Contract Mfg.
    Live From Shows
    Top News & Features
    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand

    TriMed Closes Out FDA Warning Letter

    FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System

    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

    Tyber Medical Opens $8M Office and Manufacturing Facility
    3-D Printing/Additive Mfg.
    Assembly & Automation
    Biocompatibility & Testing
    Clean Room
    Coatings/Surface Modification
    Contract Manufacturing
    Design
    Extrusion
    Finishing
    Forging & Casting
    Instruments, Cases & Trays
    International/Offshoring
    Laser Processing
    Materials
    Machining & Tooling
    Molding
    Packaging & Sterilization
    Prototyping
    Research & Developement
    Software & Quality
    Staffing, Training & Prof. Dev.
    Supply Chain

    TriMed Closes Out FDA Warning Letter

    Sounding Board: Looking Back at 2019 and Gazing at 2020

    OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application

    Clinical Study of Cell Therapy for Disc Degeneration Clears Final Planned Safety Review

    3D-Printed Graftless Bone Transplants Go to Clinical Trials
    Biologics
    Bracing/Prosthetics
    Extremities
    Imaging
    Instruments
    Large Joint
    MIS/Robotics
    Spine/Neurology
    Trauma/Sports
    Top Markets
    Sounding Board: Looking Back at 2019 and Gazing at 2020

    Molybdenum-Rhenium Biomaterial: Something ‘MoRe’?

    New Exoskeleton Shoulders Rehab Burden for Stroke Patients

    Repairing Knee Cartilage Defects with the Patient's Own Cells

    Compamed 2019 Preview Report
    Companies
    Categories
    Company Capabilities
    White Papers
    Add New Company
    International Buyers Guide Companies
    Oberg Medical

    Orchid Orthopedic Solutions

    Nelson Laboratories LLC

    NN Life Sciences

    Teleflex Medical OEM
    Industry Events
    Webinars
    • Magazine
      • Current & Past Issues
      • Features
      • Editorial
      • Departments
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • Companies
      • Categories
      • Company Capabilities
      • White Papers
      • Add Your Company
    • Manufacturing
      • 3-D Printing/Additive Mfg.
      • Assembly & Automation
      • Biocompatibility & Testing
      • Clean Room
      • Coatings/Surface Modification
      • Contract Manufacturing
      • Design
      • Extrusion
      • Finishing
      • Forging & Casting
      • Instruments, Cases & Trays
      • International/Offshoring
      • Laser Processing
      • Materials
      • Machining & Tooling
      • Molding
      • Packaging & Sterilization
      • Prototyping
      • Research & Developement
      • Software & Quality
      • Staffing, Training & Prof. Dev.
      • Supply Chain
    • Markets
      • Biologics
      • Bracing/Prosthetics
      • Extremities
      • Imaging
      • Instruments
      • Large Joint
      • MIS/Robotics
      • Spine/Neurology
      • Trauma/Sports
    • Top 10 Orthopedic Device Firms
    • Online Exclusives
    • Slideshows
    • Videos
    • Webinars
    • Events
      • Industry Events
    • Live from Show Event
    • About Us
      • About Us
      • Contact Us
      • Privacy Policy
      • Terms of Use
      • Advertise With Us
    Online Exclusives

    Straightening Out a Spinal Device’s De Novo Pathway

    Intellirod Spine and MCRA collaborated with FDA to take the first spinal device through the de novo pathway.

    Straightening Out a Spinal Device’s De Novo Pathway
    Related CONTENT
    • A Return to Memphis: An ODT Forum Preview
    • Justifying the Hype of Robotic Orthopedic Surgery
    • Intellirod Spine Receives First Ever Spine FDA De Novo Approval
    • Modernizing the Pre-habilitation Regimen
    • FDA Addresses Nitinol in Draft Guidance
    Sean Fenske, Editor-in-Chief09.16.19
    The de novo’s regulatory pathway is the third most common method for getting a product through the agency’s device review process, but hardly well understood by most firms. As such, the FDA has given the regulatory route more attention recently to make it more clear for companies seeking to use the option.
     
    Earlier this year, Intellirod Spine announced it had traversed the pathway successfully, enabling the company to bring the industry’s first spinal surgical device to market using the option. Guiding them along the way was MCRA, a clinical research organization and advisory firm with deep industry experience in regulatory, reimbursement, clinical research, healthcare compliance, and quality assurance.
     
    Taking a moment to speak with ODT, Justin Eggleton, VP of Spine Regulatory Affairs at MCRA LLC, explained why the Intellirod Spine story was significant and how it could continue to improve the industry’s understanding of the de novo pathway.
     
    Sean Fenske: Can you tell me what the Intellirod Spine technology is and its therapeutic application area?
    Justin Eggleton: The device is marketed as the LOADPRO Intraoperative Rod Strain Sensor. It is intended for use as an intra-operative tool for adjustment of posterior spine rods and to inform surgeons of rod strain. Historically, surgeons evaluate rod strain simply through tactile feel. This instrument allows surgeons to quantify rod strains and make more informed decisions while contouring the rods and correcting kyphotic deformity during surgery. The observed strains are contextualized by the strain properties of the rod materials, so rods can now be manipulated with a better understanding of rod strain relative to the material yield strain. This could help surgeons learn more about the relationship between rod strain and the common failure modes with these longer constructs.
     
    Fenske: Why is the Intellirod Spine’s de novo decision significant?
    Eggleton: It represents the first favorable de novo decision for a device intended to be used in spine surgery. Additionally, it’s a digital health technology directed toward providing more data to the surgeon during the surgical procedure. More importantly, it puts the spotlight on FDA’s more-focused decision making to ensure novel technologies are appropriately regulated based on the level of risk. The de novo pathway used to be poorly understood, which left these novel devices in an unusual regulatory predicament. FDA’s efforts to re-vamp the de novo program really helped industry to define more predictable regulatory pathways for these lower-risk devices that have no predicate devices. It should open the door to more investment in the development of these devices, for which the benefits will trickle down to patients and their quality of life. As digital health technologies continue to improve, it also provides an important pathway that could be a viable option to market.
     
    Fenske: Why haven’t products for the spine used the de novo regulatory pathway in the past?
    Eggleton: Most innovation in the spinal space has occurred historically with devices with a known FDA classification: non-fusion devices, additive manufacturing with fusion hardware, surgical instrumentation, etc. I think the lack of innovation for these novel devices is influenced by an unpredictable regulatory pathway. As such, receiving investment capital for a technology with an unpredictable regulatory pathway is not commercially viable. For a disc replacement, we know it will need a clinical study and PMA. There is significant investment, but we know this up front and it can be planned with a return on investment that can justify the resources. For a device such as LOADPRO, receiving funds 10 years ago would be complicated as the regulatory pathway was more unpredictable.
     
    Now that the de novo pathway is better defined, I do think we should begin to see the FDA and industry using it more for these devices where special controls are sufficient to justify Class II designation. It is a viable pathway; however, it is essential for industry to understand the de novo pathway has specific criteria to determine appropriateness; therefore, we will not begin to notice all of these Class III devices for high-risk devices suddenly going through the de novo pathway. In other words, the de novo pathway should not be viewed as a short cut to the market where companies can now navigate around the PMA requirements for Class III devices.
     
    Fenske: What advantages does the de novo pathway offer?
    Eggleton: To preface the answer, the de novo pathway is not an option for devices that are Class III requiring a PMA. There is an algorithm to determine if the de novo pathway to Class II is appropriate for a novel device. It starts with lack of a predicate device, different intended use, or different technological features with different safety and effectiveness questions. From there, you need to be able to describe the risks and benefits to demonstrate that general and special controls are sufficient to properly regulate the device as Class II. Once the de novo is granted, it is automatically put into Class II and industry can cite it as a predicate device for their 510(k).
     
    The requirements for future 510(k)s that all cite a de novo will vary device to device. It’s not going to be clear if the first few will also require clinical data or if the special controls can be accommodated through non-clinical testing alone. So I recommend initiating a dialogue with FDA early through a pre-submission to avoid unnecessarily driving product development in the wrong direction.
     
    De novo submissions all require clinical data specific to the subject device. A clinical foundation is necessary in order to develop special controls. The types of devices vary, and so does the type of clinical data needed. I position this as an advantage since these devices will have clinical data available upon granting of the de novo, which benefits marketing and reimbursement activities. Even if the downstream 510(k)s that claim equivalence do not require clinical data, they may face marketing barriers due to the lack of clinical data.
     
    Fenske: Can you speak to the marketing aspects further? What are the marketing benefits to this product being the first spinal device to gain a de novo?
    Eggleton: The marketing benefit is driven by the press coverage that raises awareness of the positive de novo decision granting Class II designation. Surgeons will be attracted to the technology when they study the benefits of a new instrument that allows more repeatable and clinically meaningful decisions about rod contouring to be quantified and recorded. While there is a lot we can learn from these values compared to the material’s mechanical properties, I believe the clinical benefit will be more defined over time if the community adopts these measurement techniques to posterior spine surgery. I expect this dynamic will continue to trend in this direction as surgeons are always seeking opportunities to improve the treatments they offer their patients.
     
    Fenske: Do you think this decision will have any effect on the use of the de novo pathway for future spine products?
    Eggleton: I think the work required to get to this decision will positively influence FDA’s use of the de novo pathway for future spine devices. While it’s nice to hang our hat on the positive decision, all parties involved worked really well together to ensure the risks were well understood and weighed against the benefits. This contributed to labeling discussions with FDA that benefited from the time spent understanding the device’s technological characteristics and performance data. So I think the “lessons learned” from the collaboration will certainly be a positive influence to future de novo submissions for spine devices. This applies to the FDA review and working with MCRA to support navigating the pathway.
     
    Fenske: What are the next steps for the Intellirod Spine device?
    Eggleton: Intellirod Spine can provide these details. However, their next steps are in the public domain. This includes an implantable version of LOADPRO (ACCUVISTA) that would allow rod strains to be measured post-operatively. There are several potential benefits to these data that will be assessed in future performance studies. They also have an interesting wearable sensor to measure brace compliance. While there are clinical benefits to ensuring compliance, I imagine there is interest from the insurance/reimbursement community.
     
    Fenske: Do you have any additional comments or thoughts you’d like to share?
    Eggleton: I always recommend early interaction with FDA. I think industry and FDA benefit from a collaborative process where both sides are involved in device development. This sentiment is echoed by FDA’s commitment to the Total Product Life Cycle. Today’s FDA has learned that devices are not designed in a silo and are constantly being improved. With the speed at which information is available to the public, FDA has learned that it benefits from being involved early and often. Often times, I hear industry doesn’t want to submit early due to fear of the FDA response. FDA will have the same response whether you find out now in 2019 or after you’ve spent the money and time to complete performance evaluations in 2021. Intellirod Spine is a great example of a company who interacted with FDA early and often. The feedback was not always positive, but with both sides working together, we were granted a positive de novo decision. Obviously, the LOADPRO Total Product Life Cycle will benefit from the history established with FDA.
    Related Searches
    • intellirod spine
    • regulatory
    • compliance
    • fusion
    Suggested For You
    Atlas Spine Receives 510K Clearance for Cervical Plating System Atlas Spine Receives 510K Clearance for Cervical Plating System
    Zimmer Biomet Receives FDA Clearance for Meniscal Repair Device Zimmer Biomet Receives FDA Clearance for Meniscal Repair Device
    ApiFix Receives FDA Approval for MID-C System ApiFix Receives FDA Approval for MID-C System
    DiscGenics Receives FDA Fast Track Designation DiscGenics Receives FDA Fast Track Designation
    Hidden Gems: 6 Orthopedic Technology Innovators of Note Hidden Gems: 6 Orthopedic Technology Innovators of Note
    Successful Strategies for Health Plan Medical Policy Outreach Successful Strategies for Health Plan Medical Policy Outreach
    A Look to the Future: Observations from the Top 10 Reports A Look to the Future: Observations from the Top 10 Reports
    Orthopedic Technology Innovation for Kids Orthopedic Technology Innovation for Kids
    Biomedical Startup Gears Up for U.S. Launch Biomedical Startup Gears Up for U.S. Launch
    The ABCs of HCT/Ps The ABCs of HCT/Ps
    Technology Revision: Changes in Implant Manufacturing Technology Revision: Changes in Implant Manufacturing
    The Changing World Around Orthopedic Implants The Changing World Around Orthopedic Implants
    FDA OKs AMDT Holdings FDA OKs AMDT Holdings' SixFix Hexapod Fixator Device
    FDA Addresses Nitinol in Draft Guidance FDA Addresses Nitinol in Draft Guidance
    Modernizing the Pre-habilitation Regimen Modernizing the Pre-habilitation Regimen

    Related Online Exclusives

    • 3-D Printing/Additive Mfg. | Biocompatibility & Testing | Biologics | Instruments | Materials | MIS/Robotics | Spine/Neurology
      Sounding Board: Looking Back at 2019 and Gazing at 2020

      Sounding Board: Looking Back at 2019 and Gazing at 2020

      ODT editorial advisory board members share their thoughts on the most significant events of 2019 and what they expect to watch in 2020.
      Sean Fenske, Editor-in-Chief 12.10.19

    • Materials
      Molybdenum-Rhenium Biomaterial: Something ‘MoRe’?

      Molybdenum-Rhenium Biomaterial: Something ‘MoRe’?

      A new material offers an alternative to titanium implants.
      Dave Neal, President and Founder of STAT Design 11.21.19

    • Extremities | Large Joint
      New Exoskeleton Shoulders Rehab Burden for Stroke Patients

      New Exoskeleton Shoulders Rehab Burden for Stroke Patients

      Device assists physical therapists in improving functionality for stroke patients.
      Matt Mowry, Product Manager—dryLin, igus North America 10.14.19


    • Biologics | Large Joint
      Repairing Knee Cartilage Defects with the Patient

      Repairing Knee Cartilage Defects with the Patient's Own Cells

      CO.DON CEO Ralf Jakobs explains the benefits of using autologous cell therapy to fix articular cartilage.
      Sam Brusco, Associate Editor 10.10.19

    • Compamed 2019 Preview Report

      Compamed 2019 Preview Report

      Experience the full range of supplier expertise for the medical technology industry.
      Klaus Jopp 10.08.19

    • Bracing/Prosthetics | Design | Extremities | Large Joint | Research & Development | Spine/Neurology | Trauma/Sports
      Orthopedic Technology Innovation for Kids

      Orthopedic Technology Innovation for Kids

      With pediatrics representing an underserved patient base when it comes to orthopedic solutions, a dedicated organization is seeking to change that.
      Sean Fenske, Editor-in-Chief 08.08.19


    • Imaging | MIS/Robotics | Software & Quality | Spine/Neurology
      Advanced Surgical Imaging Technologies Offer Critical Information and Improve Patient Safety

      Advanced Surgical Imaging Technologies Offer Critical Information and Improve Patient Safety

      New systems reduce exposure to radiation and improve the results of surgeries.
      Pratik Kirve, Sr. Specialist—Content Writer, Allied Analytics LLP 08.07.19

    • Intentional Design of Surface Roughness for Orthopedic Parts

      Intentional Design of Surface Roughness for Orthopedic Parts

      Roughness as a design feature in metal additive manufacturing.
      Matt Shomper, Director of Engineering, Tangible Solutions 07.22.19

    • Extremities
      Room to Grow: A Discussion on the Extremities Market

      Room to Grow: A Discussion on the Extremities Market

      A less competitive landscape and ample opportunities for innovation are helping the extremities market become one of the fastest growing sectors of orthopedics.
      Michael Barbella, Managing Editor 06.24.19


    • Extremities
      Predicting the Future of Shoulder Arthroplasty

      Predicting the Future of Shoulder Arthroplasty

      FX Shoulder USA's reverse shoulder implant is gaining traction with surgeons.
      Michael Barbella, Managing Editor 06.17.19

    • Extremities
      Extremely Simple and Efficient

      Extremely Simple and Efficient

      With more patients becoming engaged in their health, small joint device makers are designing easier, more effective treatments.
      Michael Barbella, Managing Editor 06.10.19

    • Extremities
      Extremely High Expectations

      Extremely High Expectations

      Patients are demanding small-joint solutions that eliminate pain and restore a high level of function.
      Michael Barbella, Managing Editor 06.04.19

    • 3-D Printing/Additive Mfg. | Bracing/Prosthetics
      Creating Optimal Orthotics and Prosthetics: A Case Study

      Creating Optimal Orthotics and Prosthetics: A Case Study

      An O&P practice leverages 3D scanning technology to enable custom fabricated supports for patients while saving time and money.
      Andrei Vakulenko, Business Development Officer, Artec 3D 05.31.19

    • Materials
      FDA Addresses Nitinol in Draft Guidance

      FDA Addresses Nitinol in Draft Guidance

      The focus of the DG is on the technical assessments that should be included in any regulatory submission for a device made of Nitinol.
      William A. Hyman, Professor Emeritus of Biomedical Engineering, Texas A&M University, & Adjunct Professor of Biomedical Engineering, The Cooper Union 04.30.19

    • Empowering the Six Percent

      Empowering the Six Percent

      First female AAOS president working to remove barriers to inclusion within orthopedics.
      Michael Barbella, Managing Editor 04.26.19


    Breaking News
    • Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    • TriMed Closes Out FDA Warning Letter
    • FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System
    • OrthoGrid Systems Receives FDA 510(k) Clearance for New PhantomMSK Trauma Application
    • Tyber Medical Opens $8M Office and Manufacturing Facility
    View Breaking News >
    CURRENT ISSUE

    November/December 2019

    • From Nitinol to Nanotubes: A Materials Science Roundtable
    • In Good Repair: Trauma Technologies Under Review
    • Anxious Undertones: A Review of 2019
    • View More >
    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Deerland Obtains Certification from Australia’s Therapeutic Goods Administration
    OptiMSM Shown to Improve Hair & Nail Appearance and Condition
    DCC Acquires Contract Manufacturer Ion Laboratories
    Coatings World

    Latest Breaking News From Coatings World

    Arkema: Bostik Acquires Danish Company LIP
    Axalta Adds New Epoxy Primer to Tufcote Liquid Industrial Coatings Portfolio
    Chromaflo Technologies Promotes Sergio Duenas to Country Manager of Mexico
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MedStar Health and Cleveland Clinic Innovations Awarded Grant
    3M to Sell Drug Delivery Business for $650M
    First U.S. Patient Implanted With Axonics' Sacral Neuromodulation System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Arctoris Opens Oxford R&D Facility
    Almac Group, Exostar Collaborate on IRT Experience
    Northwest Biotherapeutics Expands Management Team
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Time Features 5 Best Beauty Inventions
    CES 2020 Preview - Innovation Award Honorees in Health & Wellness
    Prada & L’Oréal Sign Long-Term Licensing Deal
    Happi

    Latest Breaking News From Happi

    Mary Kay Advocates for Equality
    Derma E Adds CBD
    Treasuring Textured Hair
    Ink World

    Latest Breaking News From Ink World

    Ripon Printers Adds Ricoh Pro C9210
    Canon Solutions America Powers University of Notre Dame Athletics' Printing Capabilities
    Worldwide Large Format Printer Shipments Down Slightly in 3Q 2019: IDC
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    GSE products provide quality assurance for Pharmalabel
    Luminer promotes Heather Bookman to prepress manager
    Materials Exchange launches to solve excess inventory issue
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    DuPont to Acquire Osmosis Specialist
    Nice-Pak to Expand in Indiana
    Hospeco Launches Compact Fem Hy Dispenser
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Europe, North America Comprise More Than 80 Percent of Global Bone Marrow Transplantation Demand
    TriMed Closes Out FDA Warning Letter
    FDA OKs Shoulder Innovations' Augmented Glenoids for Total Shoulder System
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    3D Printing Materials Market to Grow at 23.9% CAGR Through 2025: GVR
    Kyocera, TactoTek Collaborate on Injection Molded Structural Electronics Solutions
    Toray Opens R&D Innovation Center for the Future

    Copyright © 2019 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.